Telo Genomics Corp. (TSXV:TELO)

Telo Genomics Income Statement

Financials in millions CAD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Selling, General & Admin	1.25	1.38	1.44	1.52	1.03	0.65
Research & Development	0.99	1.32	1.28	1.29	1.08	0.6
Operating Expenses	2.24	2.7	2.72	2.82	2.11	1.25
Operating Income	-2.24	-2.7	-2.72	-2.82	-2.11	-1.25
Interest Expense	-0.07	-0	-0	-0.01	-0.01	-0
Other Non Operating Income (Expenses)	-0.02	-	-	-	-	-
EBT Excluding Unusual Items	-2.33	-2.7	-2.72	-2.82	-2.11	-1.26
Asset Writedown	-0.02	-0.02	-	-	-	-
Other Unusual Items	-	-	0.01	-	-	0.19
Pretax Income	-2.35	-2.72	-2.71	-2.82	-2.11	-1.07
Net Income	-2.34	-2.72	-2.71	-2.82	-2.11	-1.07
Net Income to Common	-2.34	-2.72	-2.71	-2.82	-2.11	-1.07
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	100	88	71	60	59	47
Shares Outstanding (Diluted)	100	88	71	60	59	47
Shares Change	24.37%	22.92%	18.67%	2.54%	25.11%	56.67%
EPS (Basic)	-0.02	-0.03	-0.04	-0.05	-0.04	-0.02
EPS (Diluted)	-0.02	-0.03	-0.04	-0.05	-0.04	-0.02
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Free Cash Flow	-1.32	-2.33	-2.46	-2.7	-1.82	-1.11
Free Cash Flow Per Share	-0.01	-0.03	-0.04	-0.04	-0.03	-0.02
EBITDA	-2.19	-2.68	-2.68	-2.78	-2.05	-1.19
D&A For EBITDA	0.05	0.01	0.04	0.03	0.06	0.06
EBIT	-2.24	-2.7	-2.72	-2.82	-2.11	-1.25
Advertising Expenses	-	0.08	0.22	0.09	0.06	0.07

Data Source: S&P Global Market Intelligence Last updated: Jun 2, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 4, 2026

Data Sources Report a data error